What is AB Science?
Founded in 2001, AB Science is dedicated to the research, development, and commercialization of innovative protein kinase inhibitors. The company's proprietary portfolio includes masitinib, a lead compound that has received approval in veterinary medicine and is progressing through human clinical trials. AB Science targets critical therapeutic areas such as oncology, neurological disorders, inflammatory conditions, and viral infections, aiming to provide novel treatment options for patients worldwide. The company's strategic focus on precision medicine and targeted therapies positions it as a key player in the biopharmaceutical landscape.
How much funding has AB Science raised?
AB Science has raised a total of $45.9M across 7 funding rounds:
Share Placement
$18.3M
Debt
$7.2M
Debt
$8.5M
Stock/Share Issuance
$2M
Stock/Share Issuance
$3.2M
Stock/Share Issuance
$3.7M
Private Equity
$3M
Share Placement (2020): $18.3M with participation from Undisclosed
Debt (2021): $7.2M led by Banque Populaire Group, Societe Generale, and Bpifrance
Debt (2022): $8.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Stock/Share Issuance (2025): $3.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $3.7M, investors not publicly disclosed
Private Equity (2026): $3M, investors not publicly disclosed
Key Investors in AB Science
Banque Populaire Group
Banque Populaire Group is a prominent French financial institution, likely providing debt financing and strategic banking services to support AB Science's operational and developmental needs.
Societe Generale
Société Générale, a major multinational financial services company, offers a broad spectrum of banking and investment solutions, indicating a significant role in AB Science's funding structure.
Bpifrance
Bpifrance, the French public investment bank, supports companies with credit, guarantees, and equity, suggesting a role in fostering AB Science's innovation and international growth.
What's next for AB Science?
With the recent influx of $3M in strategic capital, AB Science is poised to accelerate its pipeline development and expand its market reach. The enterprise-level backing suggests confidence from investors in the company's scientific approach and commercial potential. Future endeavors will likely involve advancing masitinib through further human clinical trials, potentially leading to broader regulatory approvals. This investment will also support the exploration of new therapeutic targets and the expansion of AB Science's operational footprint across key global markets, reinforcing its commitment to innovation in pharmaceutical research.
See full AB Science company page
